Evidence map›Paper›PMID 36148399›Full record

ArticleCancer research communications2022

Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.

Ryan M Murphy, Jason Tasoulas, Alessandro Porrello, Miranda B Carper, Yi-Hsuan Tsai, Alisha R Coffey, Sunil Kumar, Peter Yf Zeng, Travis P Schrank, Bentley R Midkiff and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Ryan M MurphyGraduate Curriculum in Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jason TasoulasDivision of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alessandro PorrelloLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Miranda B CarperDivision of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Yi-Hsuan TsaiBioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC, USA.
Alisha R CoffeyBioinformatics Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC, USA.
Sunil KumarLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Peter Yf ZengDepartment of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.
Travis P SchrankLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Bentley R MidkiffPathology Services Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC, USA.
Stephanie CohenPathology Services Core, Lineberger Comprehensive Cancer Center, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, Chapel Hill, NC, USA.
Ashley H SalazarLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michele C HaywardLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
D Neil HayesLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Andrew OlshanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gaorav P GuptaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Anthony C NicholsDepartment of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.
Wendell G YarbroughLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Chad V PecotLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Antonio L AmelioDivision of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
University of North Carolina at Chapel Hill · USWestern University · CA

Funding

Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI BURTNESS, BARBARA · 2020 to 2024
$11.8M
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation CenterUG1CA233333 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, MERKER, JASON DEREK · 2019 to 2025
$4.8M
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin MatricesR01CA258451 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL, PECOT, CHAD V · 2021 to 2025
$2.9M
Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma PathobiologyR01DE030123 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AMELIO, ANTONIO LUIGI · 2021 to 2025
$2.5M
Training Program for the Next Generation of Oral Health Researchers (NextGen)T90DE021986 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EVERETT, ERIC T. · 2011 to 2017
$2.3M
Duke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2M
Immune Regulation of Lung Squamous MetastasisR01CA215075 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PECOT, CHAD V · 2017 to 2021
$2.0M
Training in Mechanistic, Interdisciplinary Studies of Biological SystemsT32GM119999 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAMSDEN, DALE A · 2017 to 2021
$1.2M
Development of EFTX-001 to target KRAS mutations in cancerR41CA246848 · NCI · ENFUEGO THERAPEUTICS INC. · PI PECOT, CHAD V · 2020 to 2020
$225k
Investigating the role of NRF2 in promoting radioresistance in oral squamous cell carcinoma.F31DE028749 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MURPHY, RYAN MARY · 2019 to 2021
$121k
NCI NIH HHS R01 CA215075NCI NIH HHS R01 CA258451NCI NIH HHS R41 CA246848NCI NIH HHS T32 CA211056NCI NIH HHS UG1 CA233333NIDCR NIH HHS F31 DE028749NIDCR NIH HHS P50 DE030707NIDCR NIH HHS R01 DE030123NIDCR NIH HHS T90 DE021986NIGMS NIH HHS T32 GM119999
6 · The paper itself

Abstract

Over 70% of oropharyngeal head and neck squamous cell carcinoma (HNSC) cases in the United States are positive for human papillomavirus (HPV) yet biomarkers for stratifying oropharyngeal head and neck squamous cell carcinoma (HNSC) patient risk are limited. We used immunogenomics to identify differentially expressed genes in immune cells of HPV(+) and HPV(-) squamous carcinomas. Candidate genes were tested in clinical specimens using both quantitative RT-PCR and IHC and validated by IHC using the Carolina Head and Neck Cancer Study (CHANCE) tissue microarray of HNSC cases. We performed multiplex immunofluorescent staining to confirm expression within the immune cells of HPV(+) tumors, receiver operating characteristic (ROC) curve analyses, and assessed survival outcomes. The neuronal gene

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsPapillomavirus InfectionsBiomarkers, TumorHuman Papillomavirus VirusesHumansPrognosisSquamous Cell Carcinoma of Head and NeckSynaptogyrinsBiomarkers, TumorSynaptogyrinsSYNGR3 protein, humanDiagnostic biomarkersHeadHPV(+) HNSCNeck & Oral CancersPrognostic biomarkersTumor Immune Microenvironment biomarker

Identifiers

PMID36148399
PMCPMC9491693
OpenAlexW4292185501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.